Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: Updated results of a randomized phase III trial

British Journal of Haematology

Volumn 159, Issue 1, 2012, Pages 67-77

  Knauf, Wolfgang U ^a   Lissitchkov, Toshko ^b   Aldaoud, Ali ^c   Liberati, Anna M ^d   Loscertales, Javier ^e   Herbrecht, Raoul ^f   Juliusson, Gunnar ^g   Postner, Gerhard ^h   Gercheva, Liana ⁱ   Goranov, Stefan ^j   Becker, Martin ^k   Fricke, Hans Joerg ^l   Huguet, Francoise ^m   Del Giudice, Ilaria ⁿ   Klein, Peter ^o   Merkle, Karlheinz ^p   Montillo, Marco ^q  

^a Onkologische Gemeinschaftspraxis   (Germany)

^b Haematology and Transfusion Medicine National Haematological Centre   (Bulgaria)

^c Praxis für Haematologie and Onkologie   (Germany)

^d UNIVERSITY OF PERUGIA   (Italy)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HÔPITAL DE HAUTEPIERRE   (France)

^g LUND UNIVERSITY   (Sweden)

^h LBI ACR and ACR ITR Vienna   (Austria)

ⁱ UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^j UNIVERSITY HOSPITAL ST GEORGE   (Bulgaria)

^k Onkologische Schwerpunktpraxis ^*  (Germany)

^l JENA UNIVERSITY HOSPITAL   (Germany)

^m CHU PURPAN   (France)

ⁿ SAPIENZA UNIVERSITY OF ROME   (Italy)

^o Dsh Statistical Services   (Germany)

^p Oncology Consulting   (Germany)

^q OSPEDALE NIGUARDA CA GRANDA   (Italy)

more..

Author keywords

Bendamustine; Chlorambucil; Chronic lymphocytic leukaemia; Complete response; Overall survival

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; FLUDARABINE; LENALIDOMIDE; RITUXIMAB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHLORAMBUCIL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS;

EID: 84866314013     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12000     Document Type: Article

References (19)

1. Cheson, B.D., Bennet, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National cancer institute -sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
2. Dennie, T.W. & Kolesar, J.M. (2009) Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Clinical Therapeutics, 31, 2290-2311.
3. Eichhorst, B.F., Busch, R., Stilgenbauer, S., Stauch, M., Bergmann, M.A., Ritgen, M., Kranzhofer, N., Rohrberg, R., Soling, U., Burkhard, O., Westermann, A., Goede, V., Schweighofer, C.D., Fischer, K., Fink, A.M., Wendtner, C.M., Brittinger, G., Dohner, H., Emmerich, B. & Hallek, M. & the German CLL Study Group (GCLLSG). (2009) First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood, 114, 3382-3391.
4. Eichhorst, B., Hallek, M. & Dreyling, M. (2010) Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21(Suppl 5), v162-v164.
5. Fischer, K., Cramer, P., Busch, R., Stilgenbauer, S., Bahlo, J., Schweighofer, C.D., Boettcher, S., Staib, P., Kiehl, M., Eckart, M.J., Kranz, G., Goede, V., Elter, T., Buehler, A., Winkler, D., Kneba, M., Doehner, H., Eichhorst, B.F., Hallek, M. & Wendtner, C. (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. Journal of Clinical Oncology, 26, 3559-3566.
6. Flinn, I.W., Neuberg, D.S., Grever, M.R., Dewald, G.W., Bennett, J.M., Paietta, E.M., Hussein, M.A., Appelbaum, F.R., Larson, R.A., Moore, Jr, D.F. & Tallman, M.S. (2007) Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology, 25, 793-798.
7. Fortin, M., Hudon, C., Dubois, M.F., Almirall, J., Lapointe, L. & Soubhi, H. (2005) Comparative assessment of three different indices of multimorbidity for studies on health-related quality of life. Health and Quality of Life Outcomes, 3, 74.
8. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grunhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, F., Seymour, J.F., Berrebi, A., Jager, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Buhler, A., Winkler, D., Zenz, T., Bottcher, S., Ritgen, M., Mendila, M., Kneba, M., Dohner, H. & Stilgenbauer, S. (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376, 1164-1174.
9. Knauf, W.U., Lissichkov, T., Aldaoud, A., Liberati, A., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranov, S., Becker, M., Fricke, H.J., Huguet, F., Del Giudice, I., Klein, P., Tremmel, L., Merkle, K. & Montillo, M. (2009a) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology, 27, 4378-4384.
10. Knauf, W.U., Lissitchkov, T., Aldaoud, A., Liberati, A., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranov, S., Becker, M., Fricke, H.-J., Huguet, F., Del Giudice, I., Klein, K., Merkle, K. & Montillo, M. (2009b) Bendamustine in the treatment of chronic lymphocytic leukemia - consistent superiority over chlorambucil in elderly patients and across clinically defined risk groups. Blood (ASH Annual Meeting Abstracts), 114, 2367.
11. Knauf, W.U., Lissitchkov, T., Aldaoud, A., Liberati, A.M., Loscertales, J., Herbrecht, R., Juliusson, G., Postner, G., Gercheva, L., Goranov, S., Becker, M., Fricke, H.-J., Huguet, F., Del Guidice, I., Klein, P., Merkle, K. & Montillo, M. (2010) Bendamustine induces higher remission rates, prolongs progression free survival as well as time to next treatment, and improves overall survival for patients in complete remission without compromising quality of life when compared to chlorambucil in first line treatment of chronic lymphocytic leukemia. Blood (ASH Annual Meeting Abstracts), 116, 2449.
12. Leoni, L.M., Bailey, B., Reifert, J., Bendall, H.H., Zeller, R.W., Corbeil, J., Elliott, G. & Niemeyer, C. (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clinical Cancer Research, 14, 309-317.
13. Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. & Chastang, C. (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 98, 2319-2325.
14. NCCN (2011) Clinical practice guidelines in oncology: Non-Hodgkin's lymphomas. Version 3.2011. National Comprehensive Cancer Center Network, Fort Washington, PA. Available at: www.nccn.org. (accessed July 27, 2011). © National Comprehensive Cancer Network, Inc 2011, All Rights Reserved.
15. vNCI (2011) SEER Stat Fact Sheets: chronic lymphocytic leukemia. National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/statfacts/html/clyl.html (accessed July 27, 2011).
16. NICE (2011) Bendamustine for the first-line treatment of chronic lymphocytic leukaemia. NICE Technology Appraisal Guidance 216: Feb 2011. National Institute for Health and Clinical Excellence, London, UK. Available at: http://www.nice.org.uk/nicemedia/live/13343/53180/53180.pdf (accessed June 16, 2011).
17. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. & Schiffer, C.A. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1750-1757.
18. Thurmes, P., Call, T., Slager, S., Zent, C., Jenkins, G., Schwager, S., Bowen, D., Kay, N. & Shanafelt, T. (2008) Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 49, 49-56.
19. Wierda, W.G., Kipps, T.J., Mayer, J., Stilgenbauer, S., Williams, C.D., Hellmann, A., Robak, T., Furman, R.R., Hillmen, P., Trneny, M., Dyer, M.J., Padmanabhan, S., Piotrowska, M., Kozak, T., Chan, G., Davis, R., Losic, N., Wilms, J., Russell, C.A. & Osterborg, A. (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 28, 1749-1755.